This is a myopic piece, focused on a regulatory issue and targeted toward investors who may be long the stock or otherwise following OvaScience (NASDAQ:OVAS). That is to say that I won't be discussing, except where highly relevant, the other issues surrounding the stock and its next-generation technologies for improving in vitro fertilization (IVF). For investors who are less familiar with the story and want to get up to speed, I refer you to a recent SA article by a long investor, which covers much of the basics, as well as initiation reports by sell-side analysts.
The pertinent background is that OVAS has been developing the science of using a patient's own mitochondria (the energy factories in our...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|